Disruption of proteoglycan 4 (PRG4)-CD44 signaling modulates chronic synovitis in conditionally inactivated mice

Khaled A Elsaid1, Ling Zhang2, Thomas Zhao3

  • 1Department of Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, 92618, USA. elsaid@chapman.edu.

PubMed
Abstract

Insights

Proteoglycan-4 (PRG4) loss leads to chronic synovitis, which is mediated by CD44. Targeting PRG4 signaling dysfunction offers potential therapeutic strategies for osteoarthritis (OA) synovitis.

Area of Science:

  • Biochemistry
  • Immunology
  • Molecular Biology

Background:

  • Proteoglycan-4 (PRG4) is a glycoprotein that inhibits synovial macrophage activation.
  • PRG4 normally suppresses xanthine oxidase (XO) and hypoxia-inducible factor alpha (HIF-1α).
  • PRG4-CD44 interactions are crucial for maintaining synovial homeostasis.

Purpose of the Study:

  • To evaluate the role of PRG4-CD44 interaction in synovial homeostasis.
  • To investigate PRG4 signaling dysfunction in osteoarthritis (OA) synovial tissues.
  • To test the hypothesis that CD44 mediates synovitis due to PRG4 loss.

Main Methods:

  • Generated Prg4 knockout mice, crossed with Cd44 knockout mice.
  • Administered tamoxifen to induce Prg4 knockout (Prg4Off).
  • Analyzed synovial tissues from OA patients and measured XO, HIF-1α, and CD14+ cell activation.

Main Results:

  • CD44 deficiency reduced synovial pathology and macrophage activation following Prg4 inactivation.
  • High-grade synovitis tissues showed decreased PRG4 and increased CD44, XO, and HIF-1α.
  • Febuxostat treatment reduced CD14+ cell activation.

Conclusions:

  • CD44 loss abrogated synovitis associated with PRG4 loss.
  • PRG4 signaling dysfunction, marked by low PRG4 and high CD44, XO, and HIF-1α, correlates with high-grade synovitis.
  • Targeting downstream events of PRG4 loss may be a therapeutic approach for OA synovitis.